Skip to main content

Advertisement

SpringerLink
Log in

Combination therapy in stage C and D prostatic cancer: rationale and five-year clinical experience

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

In 1941, Huggins and his colleagues discovered that testicular androgens exert a stimulatory effect on prostate cancer growth. Our group has made the key observations that the human adrenals, in addition to the tests, also secrete important amounts of androgens and cancer cells exhibit a marked heterogeneity of androgen sensitivity. In fact, human adrenals secrete large amounts of precursor steroids that are converted into active androgens in peripheral tissues (including the prostate), thus providing 40% to 50% of total androgens in adult men. The action of these androgens remaining after castration can be inhibited in prostatic cancer tissue by administering a pure antiandrogen that also decreases the local concentration of dihydrotestosterone (DHT). The castration levels of serum testosterone left in men after castration have an important stimulatory activity on the growth of androgen-sensitive normal as well as cancer tissues. Cancer cells have markedly different requirements for androgens. Some cell clones can grow in the presence of minimal amounts of androgens, requiring more complete androgen blockade and more potent antiandrogens for inhibiting growth. Among the compounds recommended as antiandrogens, the most unexpected finding is that many of them are devoid of any antiandrogenic activity. In fact, medroxyprogesterone acetate, chlormadinone acetate, and megestrol acetate have androgenic activity, but do not inhibit the peripheral action of DHT in prostatic tissue. These compounds should not be classified as antiandrogens. Cyproterone acetate, on the other hand, is a mixed agonist-antagonist. The only compounds showing pure antiandrogenic activity are Flutamide and its analogues.

There is thus a need for a more complete blockade of androgens of both testicular and adrenal origins in order to exert a maximal inhibitory effect on cancer growth. We have therefore performed clinical studies in previously untreated stage D2 and C prostate cancer patients with the combination therapy using the LHRH agonist [D-Trp6, des Gly NH2 10] LHRH ethylamide and the antiandrogen Flutamide. There was a significant increase in patients with a complete response, as compared with studies limited to the removal or blockade of testicular androgens. There was also a significant decrease in the number of non-responders, an increased duration of positive response, and a decrease in the death rate. This was achieved with minimal or no side effects, thus preserving a good quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Silverberg E, Lubera JA: A review of American Cancer Society estimates of cancer cases and deaths. CA 33: 2–25, 1983

    Google Scholar 

  2. Labrie F: A new approach in the hormonal treatment of prostate cancer: complete instead of partial blockade of androgens. Int J Androl 7: 1–4, 1984

    Google Scholar 

  3. Williams G, Blooms SR: Treatment of advanced carcinoma of the prostate. Brit Med J 11: 572–572, 1984

    Google Scholar 

  4. Murphy GP, Beckley S, Brady MF, Chu M, DeKernion JB, Dhabuwala C, Gaeta JF, Gibbons RP, Loening S, McKiel CF, McLeod DG, Pontes JE, Prout Gr, Scardino PT, Schlegel JU, Schmidt JD, Scott WW, Slack NH, Soloway M: Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51: 1264–1272, 1983

    Google Scholar 

  5. Huggins C, Hodges CV: Studies of prostatic cancer. I. Effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293–297, 1941

    Google Scholar 

  6. Huggins C: Antiandrogenic treatment of prostatic carcinoma in man, approaches to tumor chemotherapy. Am Ass Adv Sci 379–383, 1947

  7. Paulson DF: The role of endocrine therapy in the management of prostatic cancer. In: Skinner DG, De Kernion JB (eds) Genitourinary Cancer. W.B. Saunders, Philadelphia, 1978, pp 288–396

    Google Scholar 

  8. Nesbit RM, Baum W: Endocrine control of prostatic carcinoma: clinical and statistical survey of 1818 cases. JAMA 143: 1317–1320, 1950

    Google Scholar 

  9. Jordan WP Jr, Blackard CE, Byar DP: Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. South Med J 70: 1411–1413, 1977

    Google Scholar 

  10. Mettlin C, Natarajan N, Murphy GP: Recent patterns of care of prostatic cancer patients in the United States: results from the surveys of the American College of Surgeons Commission on Cancer. Int Adv Surg Oncol 5: 277–321, 1982

    Google Scholar 

  11. Resnick MI, Grayhack JT: Treatment of stage IV carcinoma of the prostate. Urol Clin North Am 2: 141–161, 1975

    Google Scholar 

  12. Johnson DE, Scott WW, Gibbons RP, Prout GR, Schmidt JD, Chu JTM, Gaeta J, Sarott J, Murphy GP: National randomized study of chemotherapeutic agents in advanced prostatic carcinoma: progress report. Cancer Treat Rep 61: 317–323, 1977

    Google Scholar 

  13. Slack NH, Murphy GD, NPCP participants: Criteria for evaluating patient responses to treatment modalities for prostatic cancer. Urol Clin North Am 11: 337–342, 1984

    Google Scholar 

  14. Glashan RW, Robinson MRG: Cardiovascular complications in the treatment of prostatic carcinoma. Br J Urol 53: 624–626, 1981

    Google Scholar 

  15. Labrie F, Auclair C, Cusan L, Kelly PA, Pelletier G, Ferland L: Inhibitory effects of LHRH and its agonists on testicular gonadotropin receptors and spermatogenesis in the rat. In: Hansson V (ed) Endocrine Approach to Male Contraception. Int J Androl (suppl 2): 303–308, 1978

  16. Labrie F, Bélanger A, Cusan L, Séguin C, Pelletier G, Kelly PA, Lefebvre FA, Lemay A, Raynaud JP: Antifertility effects of LHRH agonists in the male. J Androl 1: 209–228, 1980

    Google Scholar 

  17. Faure N, Labrie F, Lemay A, Bélanger A, Gourdeau Y, Laroche B, Robert G: Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (GnRH) agonist in adult men. Fertil Steril 37: 416–424, 1982

    Google Scholar 

  18. Warner B, Worgul TJ, Drago J, Demers L, Dufau M, Max D, Santen RJ, Abbott Study Group: Effect of very high doses of D-Leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer. J Clin Invest 72: 1842–1855, 1973

    Google Scholar 

  19. Waxman JH, Was JAH, Hendry WF, Whitfield NH, Besser GM, Malpas JS, Oliver RTD: Treatment with gonadotropin-releasing hormone analogue in advanced prostatic cancer. Brit Med J 286: 1309–1312, 1983

    Google Scholar 

  20. Labrie F, Dupont A, Bélanger A, Cusan L, Lacourcière Y, Monfette G, Laberge JG, Emond JP, Fazekas ATA, Raynaud JP, Husson JM: New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 5: 267–275, 1982

    Google Scholar 

  21. Labrie F, Dupont A, Bélanger A, Lachance R, Giguère M: Long-term treatment with luteinizing hormone-releasing hormone agonists and maintenance of serum testosterone to castration concentrations. Brit Med J 291: 369–370, 1985

    Google Scholar 

  22. Farnsworth WE, Brown JR: Androgen of the human prostate. Endocr Res Commun 3: 105–117, 1976

    Google Scholar 

  23. Geller J, Albert JD, Nachtsheim DA, Loza DC: Comparison of prostatic cancer tissue dehydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. J Urol 132: 693–696, 1984

    Google Scholar 

  24. Bélanger A, Brochu M, Cliche J: Levels of plasma steroid glucuronides in intact and castrated men with prostatic cancer. J Clin Endocrinol Metab 62: 812–815, 1986

    Google Scholar 

  25. Moghissi E, Ablan F, Horton R: Origin of plasma androstanediol gucuronide in men. J Clin Endocrinol Metab 59: 417–421, 1984

    Google Scholar 

  26. Sogani PC, Ray B, Whitmore Jr WF: Advanced prostatic carcinoma: flutamide therapy after conventional endocrine treatment. Urology 6: 164–166, 1975

    Google Scholar 

  27. Stoliar B, Albert DJ: SCH 13521 in the treatment of advanced carcinoma of the prostate. J Urol 111: 803–807, 1974

    Google Scholar 

  28. Sanford EJ, Paulson DF, Rohner TJ, Drago JR, Santen RJ, Bardin CW: The effects of castration on adrenal testosterone secretion in men with prostatic carcinoma. J Urol 118: 1019–1021, 1977

    Google Scholar 

  29. Robinson MR, Shearer RJ, Fergusson JD: Adrenal suppression in the treatment of carcinoma of the prostate. Brit J Urol 46: 555–559, 1974

    Google Scholar 

  30. Huggins C, Scott WW: Bilateral adrenalectomy in prostatic cancer. Ann Surg 122: 1031–1041, 1945

    Google Scholar 

  31. Labrie F, Dupont A, Bélanger A. Complete androgen blockade for the treatment of prostate cancer. In: De Vita VT, Hellman S, Rosenberg SA (eds) Important Advances in Oncology. J. B. Lippincott, Philadelphia, 1985, pp 193–217

    Google Scholar 

  32. Labrie F, Veilleux R: A wide range of sensitivities to androgens develops in cloned Shionogi mouse mammary tumor cells. Prostate 8: 293–300, 1986

    Google Scholar 

  33. Fowler JE, Whitmore Jr WF: The response of metastatic adenocarcinoma of the prostate of exogenous testosterone. J Urol 126: 372–375, 1981

    Google Scholar 

  34. Bartsch W, Knabbe M, Voigt KD: Regulation and compartmentalization of androgens in rat prostate and muscle. J Steroid Biochem 19: 929–937, 1983

    Google Scholar 

  35. Marchetti B, Plante M, Poulin R, Labrie F: Dramatic response of prostate weight and ornithine decarboxylase to low levels of testosterone in castrated rats. J Steroid Biochem 36: 32S, 1985

  36. Labrie F, Dupont A, Bélanger A, Giguère M, Lacorucière Y, Emond J, Monfette G, Bergeron V: Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem 23: 833–841, 1985

    Google Scholar 

  37. Labrie F, Dupont A, Bélanger A, St-Arnaud R, Giguère M, Lacourcière Y, Emond J, Monfette G: Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocr Rev 7: 67–74, 1986

    Google Scholar 

  38. Labrie F, Dupont A, Bélanger A, Giguère M, Borsanyi JP, Lacourcière Y, Emond J, Monfette G, Lachance R: The importance of combination therapy with Flutamide and castration (LHRH agonist or orchiectomy) in previously untreated as well as previously treated patients with advanced prostate cancer. In: Hormonal Manipulation of Cancer: Peptides, Growth Factors and (Anti)-steroidal Agents. Raven Press, New York, 1986, pp 291–300

    Google Scholar 

  39. Dexter DL, Calabresi P: Intraneoplastic diversity. Biochim Biophys Acta 694: 97–112, 1982

    Google Scholar 

  40. Hamada H, Neumann F, Junkmann K: Intrauterine antimaskuline beeinflussing von rattenfetendurch ein stark gestagen wirksames steroid. Steroid Acta Endocrinol 44: 330–388, 1963

    Google Scholar 

  41. Neri R, Monahan MD, Meyer JG, Afonso BA, Tabachnick IA: Biological studies on an antiandrogen (SH-714). Eur J Pharmacol 1: 438–444, 1967

    Google Scholar 

  42. Dorfmann RI: Antiandrogens. In: Jarnes V, Martini L (eds) Proc of the Third Int Congress on Hormonal Steroids. Excerpta Medica, Amsterdam, 1971, p 995

    Google Scholar 

  43. Johnson DE, Kaesler KE, Ayala AG: Megestrol acetate for treatment of prostatic carcinoma. Br J Urol 53: 624–630, 1981

    Google Scholar 

  44. Poyet P, Labrie F: Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Mol Cell Endocrinol 32: 283–288, 1985

    Google Scholar 

  45. Mowszowicz I, Bieber DE, Chung KW, Bullock LP, Bardin CW: Synandrogenic and antiandrogenic effect of progestins: comparison with nonprogestational antiandrogens. Endocrinology 95: 1589–1599, 1974

    Google Scholar 

  46. Graf KJ, Kleinechke RI, Neumann F: The stimulation of male duct derivatives in female guinea pigs with an antiandrogen cyproterone acetate. J Reprod Fertil 39: 311–317, 1974

    Google Scholar 

  47. Tisell LE, Salander H: Androgenic properties and adrenal depressant activity of megestrol acetate observed in castrated male rats. Acta Endocrinol 78: 316–324, 1975

    Google Scholar 

  48. Noguchi S, Nishizama Y, Uchida N, Yamaguchi K, Sato B, Kitamura Y, Matsumoto K: Stimulative effect of physiological doses of androgens or pharmacological doses of estrogen on growth of Shionogi carcinoma 115 in mice. Cancer Res 45: 5746–5750, 1985

    Google Scholar 

  49. Pavone-Maculuso M, De Voogt HJ, Viggiano G, Barasolo E, Hardennois B, De Pauw M, Silvester R: Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of the randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol 1: 624–631, 1986

    Google Scholar 

  50. Labrie F, Dupont A, Bélanger A, Lacourcière Y, Raynaud JP, Husson JM, Gareau J, Fazekas ATA, Sandow J, Monfette G, Girard JG, Emond J, Houle JG: New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate 4: 579–584, 1983

    Google Scholar 

  51. Kramer CY: Extension of multiple-range tests to groups means with unique numbers of replications. Biometrics 12: 307–310, 1956

    Google Scholar 

  52. Armitage T: Statistical methods in Medical Research. Blackwell Scientific Publications, Oxford, 1971

    Google Scholar 

  53. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. Am Stat Ass J 53: 457–481, 1958

    Google Scholar 

  54. Smith JA, Glode LM, Wettlaufer JN, Stein BS, Glass AG, Max TD, Enber D, Jagst CL, Murphy GT: Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of the prostate. Urology 1985: 20: 106–112, 1985

    Google Scholar 

  55. The Leuprolide Study Group: Leuprolide versus diethylstilbestrol for metastatic prostate cancer. New Engl J Med 311: 1281–1286, 1984

    Google Scholar 

  56. Brendler H, Prout GR Jr: A cooperative group study of prostatic cancer. Stilbestrol versus placebo in advanced progressive disease. Cancer Chemother Rep 16: 323–327, 1962

    Google Scholar 

  57. Labrie F, Luthy I, Veilleux R, Simard J, Bélanger A, Dupont A: New concepts on the androgen sensitivity of prostate cancer. In: Murphy G (ed.) Second Int Symposium on Prostate Cancer. Alan R. Liss, Inc., New York, 1987 (in press)

    Google Scholar 

  58. Luthy I, Labrie F: Development of androgen resistance in mouse mammary tumor cells can be prevented by the antiandrogen flutamide. Prostate 10: 89–94, 1987

    Google Scholar 

  59. Simard J, Luthy I, Guay J, Bélanger A, Labrie F: Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. Mol Cell Endocrinol 44: 261–270, 1986

    Google Scholar 

  60. Asselin J, Mélançon R, Moachon G, Bélanger A: Characteristics of binding to estrogen, androgen, progestin and glucocorticoid receptors in 7,12-dimethylbenz(a)anthracene-induced mammary tumors and their hormonal control. Cancer Res 40: 1612–1622, 1980

    Google Scholar 

  61. Kahan A, Delrieu F, Amor B, Chiche R, Steg A: Disease flare induced by D-Trp6-GnRH analogue in patient with metastatic prostatic cancer. Lancet 1: 971, 1984

    Google Scholar 

  62. Bélanger A, Dupont A, Labrie F: Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer. J Clin Endocrinol Metab 59: 422–426, 1984

    Google Scholar 

  63. Moore RJ, Gazak JM, Wilson JD: Regulation of cytoplasmic dihydrotestosterone binding in dog prostate by 17β-estradiol. J Clin Invest 63: 351–357, 1979

    Google Scholar 

  64. Mobbs BG, Johnson IE, Connolly JG, Thompson J: Concentration and cellular distribution of androgen receptor in human prostatic neopolasia: can estrogen treatment increase androgen receptor content? J Steroid Biochem 19: 1279–1290, 1983

    Google Scholar 

  65. Gibbons RP, Mason JT, Correa RJ Jr, Cummings KB, Taylor WJ, Hafermann N, Richardson RG: Carcinoma of the prostate: local control with external beam radiation therapy. J Urol 121: 310–312, 1979

    Google Scholar 

  66. Tomlinson RL, Currie DP, Boyce WH: Radical prostatectomy: palliation for stage C carcinoma of the prostate. J Urol 117: 85–87, 1977

    Google Scholar 

  67. Paulson DF: Treatment of locally confined prostaic cancer: radiotherapy versus surgery-limits of curability. In: Kurth KIH, Debryene FMJ, Schraeder FH, Splinter TAW, Wagener TDJ (eds) Progress and Controversies in Oncological Urology. Alan R. Liss, New York, 1984, pp 483–492

    Google Scholar 

  68. Cupps RE, Utz DC, Fleming TR, Carson CC, et al. Definitive radiation therapy for prostatic carcinoma: Mayo Clinic Experience. J Urol 124: 855–859, 1980

    Google Scholar 

  69. Smith PH, Suciu S, Robinson MRG, Richards B, Bestable JRG, Glashan RW, Boussioux C, Lardennois B, William RE, De Pauw M, Sylvester R: A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer. J Urol 136: 619–623, 1986

    Google Scholar 

  70. Grayhack JT, Kozlowski JM: Endocrine therapy in the management of advanced prostatic cancer: the case for early initiation of treatment. Urol Clin North Am 7: 639–643, 180

  71. Veterans Administration Cooperative Urological Research Group (VACURG): Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124: 1011–1017, 1967

    Google Scholar 

  72. Hedlund PO, Gustafsson H, Sjogren S: Cardiovascular complications to treatment of prostatic cancer with estramustine phosphate (Estracyt) or conventional oestrogen. A follow-up of 212 randomized patients. Scand J Urol Nephrol [Suppl] 55: 103–105, 1980

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular Endocrinology, Laval University Medical Center, G1V 4G2, Quebec, Canada

    Fernand Labrie, André Dupont, Alain Bélanger, Lionel Cusan, Michel Giguère, Isabel Luthy, Daniel Bégin, Claude Labrie & Jacques Simard

  2. Department of Medicine, Laval University Medical Center, G1V 4G2, Quebec, Canada

    Fernand Labrie, André Dupont & Lionel Cusan

  3. Department of Nuclear Medicine, Laval University Medical Center, G1V 4G2, Quebec, Canada

    Yves Lacourcière

  4. Department of Urology, Hotel-Dieu Hospital, St-Jerome, Canada

    Yves Lacourcière

  5. Department of Urology, Hotel-Dieu Hospital, St-Jerome, Canada

    Gérard Monfette

  6. Department of Urology, Hotel-Dieu Hospital, Levis, Canada

    Jean Emond

Authors
  1. Fernand Labrie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. André Dupont
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alain Bélanger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lionel Cusan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michel Giguère
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yves Lacourcière
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Isabel Luthy
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Daniel Bégin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Claude Labrie
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jacques Simard
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Gérard Monfette
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jean Emond
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Labrie, F., Dupont, A., Bélanger, A. et al. Combination therapy in stage C and D prostatic cancer: rationale and five-year clinical experience. Cancer Metast Rev 6, 615–636 (1987). https://doi.org/10.1007/BF00047470

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00047470

Key words

Search

Navigation